- Adaptive Biotechnologies Corp (NASDAQ: ADPT) launched a clinical T-cell-based test kit to confirm recent or prior COVID-19 infection.
- T-Detect is currently under review by the FDA for Emergency Use Authorization.
- Separately, the Company also
Full story available on Benzinga.com